Haruto Hangover Defencepatch
Glutathione
Youngwoo Co.,ltd
Human Otc Drug
NDC 80094-0001Haruto Hangover Defencepatch also known as Glutathione is a human otc drug labeled by 'Youngwoo Co.,ltd'. National Drug Code (NDC) number for Haruto Hangover Defencepatch is 80094-0001. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Haruto Hangover Defencepatch drug includes Glutathione - 1.422 mg/100mg . The currest status of Haruto Hangover Defencepatch drug is Active.
Drug Information:
| Drug NDC: | 80094-0001 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Haruto Hangover Defencepatch |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Glutathione |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Youngwoo Co.,ltd |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Patch |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | GLUTATHIONE - 1.422 mg/100mg
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED DRUG OTHER |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Oct, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | YOUNGWOO CO.,LTD
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | GAN16C9B8O
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 80094-0001-1 | 3 mg in 1 PATCH (80094-0001-1) | 01 Oct, 2020 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Hangover relief
Product Elements:
Haruto hangover defencepatch glutathione thiamine hydrochloride glutathione glutathione
Indications and Usage:
Stick the patch to target areas of concern and gently press down on the patch
Warnings:
1. do not use in the following cases(eczema and scalp wounds) 2.side effects 1)due to the use of this druf if rash, irritation, itching and symptopms of hypersnesitivity occur dicontinue use and consult your phamacisr or doctor 3.general precautions 1)if in contact with the eyes, wash out thoroughty with water if the symptoms are servere, seek medical advice immediately 2)this product is for exeternal use only. do not use for internal use 4.storage and handling precautions 1)if possible, avoid direct sunlight and store in cool and area of low humidity 2)in order to maintain the quality of the product and avoid misuse 3)avoid placing the product near fire and store out in reach of children
Dosage and Administration:
For external use only
Package Label Principal Display Panel:
Label